Treatment outcomes of pachychoroid neovasculopathy with photodynamic therapy and anti-vascular endothelial growth factor

• Published in: Indian journal of ophthalmology Vol. 67; no. 10; pp. 1678 - 1683
• Main Authors: Roy, Rupak, Saurabh, Kumar, Shah, Dhaivat, Goel, Sugandha
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01-10-2019; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd; Wolters Kluwer - Medknow; Wolters Kluwer Medknow Publications
• Subjects: Aflibercept; Aged; Angiogenesis Inhibitors - administration & dosage; Antibodies; Care and treatment; Choroid - blood supply; Choroid - diagnostic imaging; Choroid - drug effects; Choroidal Neovascularization - diagnosis; Choroidal Neovascularization - drug therapy; Clinical outcomes; Consent; Drug Therapy, Combination; Endothelial growth factors; Eye diseases; Fluorescein Angiography - methods; Follow-Up Studies; Fundus Oculi; Health aspects; Humans; Intravitreal Injections; Medical imaging; Microcirculation disorders; Middle Aged; Monoclonal antibodies; OCT; Original; pachychoroid disease; pachychoroid neovasculopathy; Patient outcomes; Patients; Photochemotherapy; Photochemotherapy - methods; Photodynamic therapy; Photosensitizing Agents - therapeutic use; Ranibizumab; Ranibizumab - administration & dosage; Retrospective Studies; Tomography; Tomography, Optical Coherence; Treatment Outcome; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity; India; OCT; pachychoroid neovasculopathy; pachychoroid disease
• ISSN: 0301-4738; 1998-3689
• DOI: 10.4103/ijo.IJO_1481_18

Purpose: To describe treatment outcomes of eyes with pachychoroid neovasculopathy (PNV) with PDT and anti-(vascular endothelial growth factor) VEGF therapy. Methods: Retrospective interventional case series. Records of six consecutive cases of PNV were reviewed. Four cases were treated with PDT+ inj ranibizumab. Two cases underwent only PDT. Final visual outcomes and functional outcome including macular status and choroidal thickness were assessed. Results: We analysed six eyes of six patients with PNV. There were four males and two females. Mean age of the patients was 56.5 years. Mean duration of follow up was 8.2 months. All patients received reduced fluence PDT. Four patients received ranibizumab along with PDT; mean BCVA at presentation was 0.41 log MAR units and mean BCVA at final follow up was 0.44 log MAR units. There was significant improvement at final follow up (P = 0.03). Mean subfoveal choroidal thickness (SFCT) at presentation was 445 microns and mean SFCT at final follow up was 293 microns. There was a significant reduction at final follow up (P = 0.02). Conclusion: PDT with or without ranibizumab appears to be an effective treatment modality for PNV.